FOCUSED ON WOMEN'S HEALTH and hormone-sensitive cancer for healthy aging worldwide

Discover our research

Our solution

A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.

Find out about Intrarosa™

Our goal as a Quebec company


Our main goal is to offer all women in the world, in addition to the treatment of vaginal atrophy, the benefits of effective, physiological and non-negative treatments for all menopausal problems, including hot flashes, sexual dysfunction, bone loss and muscle loss.

Research and Development

Latest News

Read the news

Endoceutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

April 25, 2019

Québec City, Canada, April 25th, 2019; Endoceutics announced today that Dennis Turpin, President and Chief Executive Officer of Endoceutics, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference.

Endoceutics, Université Laval, and CHU de Québec settle their disputes

March 27, 2019

Québec City, Canada, March 27, 2019 – Endoceutics Inc., Université Laval, and CHU de Québec-Université Laval (CHU de Québec-UL) are pleased to announce that they have reached an agreement to resolve all their disputes with respect to economic benefits deriving from research. Université Laval and CHU de Québec-UL will share in the anticipated economic benefits associated with Intrarosa™.

Death of Dr. Fernand Labrie

January 17, 2019

Quebec City, January 17, 2019 – It is with great sadness that Endoceutics management announces the death of its president and founder Dr. Fernand Labrie at the age of 81.